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Complement is activated in kidney by endotoxin but does not tion rate is associated with the pathological lesion of
cause the ensuing acute renal failure. acute tubular necrosis. ARF in the setting of sepsis often
Background. Acute renal failure (ARF) in sepsis occurs occurs despite relatively modest levels of hypotension,when the release of multiple inflammatory mediators is induced
implying that some factor(s) other than ischemia aloneby bacterial endotoxins. C3 mRNA is markedly up-regulated
is involved. In sepsis, bacterial products such as lipopoly-in mouse kidney after exposure to lipopolysaccharide (LPS).
We hypothesized that LPS could induce tubular synthesis and saccharide (LPS) trigger the release of multiple inflam-
secretion of C3, leading to activation of the complement cas- matory mediators, including the complement cascade [1].
cade and direct renal tubular injury.
Injection of animals with LPS can serve as a useful modelMethods. ARF was induced in mice by intravenous injection
of endotoxemia, leading to widespread cytokine releaseof LPS and was confirmed by an acute rise in blood urea nitrogen
(BUN) and histologically by acute tubular necrosis. Three sepa- and resulting in ARF [2].
rate strategies were used to investigate the role of the comple- Several complement regulatory proteins serve to in-
ment system in this model of ARF: (1) Crry-Ig, a recombinant hibit and contain the complement cascade. One key regu-protein containing the potent murine complement C3 activation
lator in the mouse is Crry (complement receptor 1-relatedinhibitor Crry was injected at the same time as LPS (N 5 8).
gene/protein y) [3–6], a membrane-bound C3 convertase(2) LPS was injected into transgenic mice overexpressing Crry
in glomeruli and tubules (N 5 8), and (3) LPS was injected inhibitor present in a variety of tissues, including the kid-
into C3-deficient mice (N 5 5). ney [7, 8]. Various strategies have been used to show that
Results. Compared with unmanipulated mice, C3 staining increasing the degree of complement inhibition decreasesby immunofluorescence (IF) microscopy in mice injected with
injury in rodent models of glomerulonephritis [9–11].LPS was greater in renal cortical tubular cells (IF score of 2.1 6
0.1 vs. 1.4 6 0.2 in controls, P 5 0.013), most prominently at Although the liver is the major source of serum com-
the basolateral surface. LPS injection led to a 16- to 42-fold plement, other tissues, including kidney, have been shown
increase in urinary C3 excretion. Despite reduction or complete to synthesize components of the complement system.
elimination of renal C3 with maneuvers suppressing comple-
Renal cortical C3 mRNA levels are acutely increasedment activation, BUN values were not statistically different
in vivo in mice after LPS injection [12]. Additionally,across all groups. In no experiment did BUN values correlate
with the extent of C3 staining. cultured human proximal tubular cells immediately syn-
Conclusion. Although LPS up-regulates renal C3 synthesis, thesize and secrete functionally active C3 after exposure
resulting in basolateral tubular C3 deposition, this is not re- to various cytokines, including tumor necrosis factor-a,sponsible for LPS-induced ARF in mice.
interleukin-1a, interferon-g, or interleukin-2 [13, 14].
There is evidence that under immunologic activation,
such as occurs with transplant rejection, tubular cells canSepsis is a common cause of acute renal failure (ARF),
produce C3 [15] and contribute to the circulating C3an entity in which the abrupt decline in glomerular filtra-
pool [16].
Basolateral deposition of complement around renal
tubules has been demonstrated in chronic renal paren-Key words: acute tubular necrosis, C3, lipopolysaccharide, recombi-
nant proteins, transgenic mice, knockout mice, sepsis. chymal disease, which has been attributed to comple-
ment activation by the high interstitial ammonia concen-Received for publication October 18, 1999
tration [17]. Human proximal tubular cells in culture areand in revised form March 23, 2000
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ment [18], terminating in the binding of the C5b-9 mem-Ó 2000 by the International Society of Nephrology
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brane attack complex to the cellular surface, followed gous recombination (C32/2) and their wild-type con-
by release of inflammatory mediators such as arachidonic trols (C31/1), on a 129SvJ and C57BL/6 mixed back-
acid metabolites, interleukin-6, and tumor necrosis fac- ground, were generated as previously described [28, 29].
tor-a [19]. The luminal brush border may be more vul- Normal CD-1 mice were purchased from Harlan Sprague
nerable to complement-mediated injury because it lacks Dawley (Indianapolis, IN, USA).
the complement regulatory proteins present on the baso-
Crry-Iglateral cell surface [20]. This has led to the hypothesis
that the chronic tubular damage seen with long-standing A Crry-Ig chimera was used in these studies [11]. The
proteinuria is due to luminal deposition of filtered com- construct used to produce this uses the CMV promoter
ponents of complement [21]. In support of this, luminal and encodes a signal peptide followed by the five short
complement deposition has been detected in several ani- consensus repeats of Crry and the hinge, CH2 and CH3
mal models of nonimmunologic proteinuria [22–24]. domains of mouse IgG1, a noncomplement fixing isotype.
Ischemic damage itself, independent of endotoxin, The circulating half-life of Crry-Ig is approximately 40
may impair the ability of renal tubular cells to regulate hours, and thus, a single intravenous dose of 3 mg confers
the complement cascade and therefore increase comple- lasting complement inhibition for acute studies [11]. To
ment activation on their surface [25]. In addition to the serve as an appropriate control for Crry-Ig, MOPC-21,
previously mentioned mechanisms, all of which would an irrelevant monoclonal murine IgG1 antibody, was pu-
involve the alternative pathway, ischemic damage to cells rified from ascites (Sigma, St. Louis, MO, USA) via ion-
can cause exposure of previously hidden cell membrane exchange chromatography (Amersham-Pharmacia-Bio-
antigens and binding of “natural antibodies,” of the tech, Uppsala, Sweden).
strongly complement-activating IgM isotype, leading to
propagation of the classical pathway [26]. Beyond their Basic experimental design
local inflammatory effects, complement cleavage prod- A model for ARF in mice was developed in which
ucts C3a and C5a have vascular effects [27] that could animals were injected intravenously with LPS (E. coli
contribute to changes in renal hemodynamics in ARF. serotype O111:B4 LPS; Sigma). As shown in Figure 1,
Thus, by a variety of mechanisms, the complement sys- there was a dose–response relationship between the
tem may be a key effector of ARF in sepsis. amount of LPS injected and the resultant ARF. Based
Given these interactions, we hypothesized that the
on this dose–response relationship, 0.15 mg per mouse
complement system could potentially play a key role in
was selected as the optimal dose. Three experiments
endotoxemic ARF. LPS could trigger increased local
were conducted to determine the influence of the com-synthesis, activation, and deposition of C3 either at the
plement system in endotoxin-induced ARF. In the firstbasolateral or luminal surface of the tubules, resulting in
experiment, eight normal CD-1 mice were injected intra-propagation of the alternative and terminal complement
venously with 0.15 mg of LPS concurrently with 3 mg ofpathways leading to tubular cell damage and acute tubu-
Crry-Ig. These were compared with a control grouplar necrosis. This study examines the effect of three dif-
of eight normal CD-1 mice injected with the same doseferent strategies to inhibit complement on LPS-induced
of LPS together with 3 mg of MOPC-21 IgG1. For therenal injury.
second experiment, eight Crry transgenic mice and eight
littermate animals lacking the transgene were injected
METHODS with 0.15 mg LPS. In the third experiment, five C32/2
mice were injected with 0.15 mg LPS and compared withMice
five C31/1 mice treated identically.Transgenic mice expressing recombinant soluble Crry
Mice were anesthetized with methoxyflurane inhala-directed by the metallothionein-I promoter were used
tion. After initial injection, animals were placed in meta-in this study. These mice have circulating levels of soluble
bolic cages for urine collection overnight. In all mice,Crry that are complement inhibitory, and high intrinsic
serum was obtained via retro-orbital bleeding for base-renal production of Crry, including in glomeruli and tu-
line blood urea nitrogen (BUN) immediately before in-bules [10]. The Crry transgenic animals used in this study
jection and 20 hours after injection. Following this, ani-were derived from a single founder line and are on a
mals were sacrificed and renal tissue harvested for lightCD-1 background. In all animals, the presence of the
and immunofluorescence (IF) microscopy.Crry transgene was documented by polymerase chain
For comparison of urinary and tissue C3, three normalreaction (PCR), and soluble Crry in sera was identified
CD-1 mice undergoing no experimental manipulationby enzyme-linked immunosorbent assay (ELISA) [10].
were placed in metabolic cages, and urine was collectedAs controls, littermate animals that lacked the Crry
overnight. These mice were then sacrificed, and kidneytransgene were used.
Mice in which the C3 gene was inactivated by homolo- tissue was taken for IF microscopy.
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Fig. 1. Lipopolysaccharide (LPS) leads to
acute renal failure (ARF) in a dose-dependent
fashion. Blood urea nitrogen (BUN) measure-
ments taken 24 hours after intravenous injec-
tion of various doses of LPS are shown as
mean values 6 SEM. Baseline BUN values
were 21.6 6 0.9 mg/dL.
Analysis of serum and urine pel, Organon Teknika Corp., Durham, NC, USA). IF
staining scores in glomeruli and tubules were compiledBlood urea nitrogen concentration was determined
by an observer blinded to the origin of the samples.by the urease-glutamate dehydrogenase assay using a
Beckman CX5CE autoanalyzer.
Statistical analysisSerum and urinary levels of mouse C3 and albumin
All data are reported as the mean 6 SEM. A compari-were measured by previously described ELISA protocols
son between variables at baseline and following LPS[30, 31]. The C3 ELISA will react with C3 in its native
administration was made by paired t-testing. Comparisonor activated forms [30] and was sensitive to 1.5 ng/mL.
between an experimental group and its respective con-When an animal had undetectable urinary C3 by this
trol group was done using an unpaired t-test. A correla-technique, it was considered to be zero. As expected, C3
tion between two variables within groups was done bywas not detected in C32/2 mice, and this group was not
univariate linear regression. Statistical calculations wereentered in analysis of sera C3 levels. Creatinine concen-
done using Minitab software (State College, PA, USA).tration was measured by the modified rate Jaffe´ reaction
using a Beckman CX5CE autoanalyzer. The fractional
excretion of C3 (FEC3) was determined by dividing CC3 RESULTS
by CCr, leading to the following calculation: [plasma creati- ARF occurs after endotoxin administrationnine][urine C3]/[urine creatinine][plasma C3]. FEAlbumin
As shown in Figure 1, mice given LPS intravenouslyrelative to creatinine was determined in an analogous
developed ARF. Excessive mortality was observed atfashion. For these calculations, we used normal values in
doses above 0.15 mg. As all animals receiving 0.15 mgthe mouse for serum creatinine (3 mg/mL), C3 (3 mg/mL),
developed renal failure, this dose was chosen for subse-and albumin (37 mg/mL) derived in our laboratory.
quent studies in which we determined the effects of in-
Renal tissue processing hibiting complement activation on the resultant ARF.
Three different experimental strategies (Crry-Ig in nor-A sagittal section of renal tissue was fixed in buffered
mal mice, Crry transgenic mice, and C32/2 mice), eachformalin. Five micrometer sections were stained with peri-
with its relative advantage in this model, were used toodic acid-Schiff and were processed for light microscopic
determine conclusively the effects of complement in thisevaluation. A renal tubular injury score was adapted from
LPS-mediated ARF.that described by Nomura et al [32], incorporating tubu-
In all groups of animals, baseline BUN values werelar cast formation, dilation, and degeneration, each scored
no different prior to LPS injection (22.8 6 0.7 mg/dL inby a blinded observer from 0 to 3; the composite score
the 6 groups of animals). Following LPS injection, BUNreported adds all three values together.
rose acutely in every animal in each experiment. In theFor IF microscopy, tissue was snap frozen in isopen-
three experiments, only one animal, in the C31/1 group,tane on dry ice. Four micrometer cryostat sections were
died. Individual data points are shown in Figure 2. How-processed for direct IF microscopy as described pre-
viously [33] using FITC-conjugated anti-mouse C3 (Cap- ever, no statistically significant differences were found
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Fig. 2. Effect of complement inhibition on
LPS-induced ARF. BUN values obtained 20
hours after LPS injection are shown for each
group. Each data point corresponds to an indi-
vidual animal. Symbols are: (d) groups in
which a complement-reducing strategy was
used; (s) respective control groups. No sig-
nificant difference in BUN was found between
any experimental group and its particular con-
trol group. Baseline BUN values were 22.8 6
0.7 mg/dL in the six groups of animals.
between any of the experimental and respective control nificantly less tubular C3 staining in the Crry-transgenic
group compared with its control group (P 5 0.012; Fig. 6),groups. These results show that ARF occurs with endo-
toxin administration, but suggest that complement is un- and as expected, no C3 staining in C32/2 mice (P #
0.001 vs. C31/1 animals). Glomerular C3 staining wasimportant in the pathogenesis of this condition.
minimal in all experimental and control groups (data not
Light microscopy shown). C3 staining did not correlate with BUN values.
Thus, complement activation and deposition occur withTissue from all animals in both experimental and con-
trol groups showed evidence for tubular injury with tubu- LPS activation, but appear to not be responsible for
the ARF.lar dilation, vacuolization, luminal debris, and brush bor-
der attenuation (Fig. 3B). Quantitatively, however, this
Serum and urinary C3 and albuminwas of moderate severity and indistinguishable in degree
between experimental and control groups receiving LPS. Serum C3 levels increased following LPS administra-
tion, although this was not statistically significant (3.10 6In confirmation that an LPS dose of 0.15 mg led to
adequate renal injury, the tubular injury score at a dose 0.22 and 3.60 6 0.22 mg/mL before and after LPS admin-
istration, respectively, P 5 0.11). With the use of sensi-of 0.15 mg was comparable to that seen with 0.5 mg in
normal CD-1 mice (respective injury scores of 3.0 6 0.2 tive ELISA techniques, there was detectable urinary C3
(range, 0 to 198 ng/mL) and albumin (range, 4.8 to 15.3and 3.7 6 0.8, N 5 4, P 5 NS). Glomeruli in all groups
of animals were normal (Fig. 4). mg/mL) in normal animals. FEC3 and FEAlbumin are shown
in Table 1. Upon injection of LPS, urinary C3 excretion
Tissue C3 was elevated between 16- and 42-fold relative to normal
animals (P , 0.001 vs. unmanipulated mice), with theNormal unmanipulated mice had focal segmental tubu-
lar staining for C3, as well as discontinuous linear staining obvious exception of C32/2 mice (Table 1). Urinary
albumin was also elevated in all mice receiving LPS com-of Bowman’s capsule. This tubular staining was at the
basolateral aspect of the tubules and present in cortical pared with unmanipulated normals (P , 0.001), but was
statistically similar between each experimental groupbut not medullary areas (data not shown). This is not
artifactual, as this staining pattern is absent in C32/2 and its control group. The absolute and relative excretion
of albumin was consistently elevated compared with uri-mice. In normal mice given LPS, there was increased
C3 deposition in the basolateral aspects of tubules (IF nary C3 in all groups (Table 1).
There was a positive correlation of urinary C3 withstaining scores in normal and LPS-injected mice, 1.4 6
0.2 and 2.1 6 0.1, respectively, P 5 0.013). urinary albumin (r 5 0.66, P , 0.001).
There was no correlation in pooled data or individualThe tubular IF scores in the various groups are shown
graphically in Figure 5. There was a trend for less tubular experiments between BUN and either urinary excretion
of C3 or albumin as absolute values or as fractionalC3 staining in the experimental group receiving Crry-Ig
when compared with its corresponding control group, excretions relative to urinary creatinine. In addition,
there was no correlation in pooled data or individualbut these were not statistically different. There was sig-
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Fig. 3. LPS-induced ARF is associated with tubular damage. Compared with a normal control kidney (A), animals injected with LPS showed
changes of tubular dilation (asterisks), vacuolization (arrows) and brush border attenuation and sloughing (arrowhead; B). This was indistinguishable
in severity between experimental and control groups given LPS.
Fig. 4. Glomeruli from mice with LPS-induced
ARF are normal. Representative glomeruli
from a normal control (A) and LPS-injected
animal (B) are shown.
Fig. 5. Immunofluorescence (IF) scores for tubular C3 staining in mice
receiving LPS. Data shown are mean 6 SEM. *P 5 0.012; **P # 0.001
vs. corresponding control groups.
Fig. 6. Tubular C3 staining in mice with LPS-induced ARF. After LPS administration, tubules stained for C3 by IF microscopy, in a predominantly
basolateral and cortical distribution. Animals positive for the Crry transgene showed significantly less tubular C3 staining (A) than transgene
negative controls (B).
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Table 1. Urinary excretion of C3 and albumin in the different groups of animals
Group LPS CC3/CCr (3106) CAlbumin/CCr (3106) CAlbumin/CC3
CD-1 — 0.260.2 3.160.8 6.3a
CD-1 1 MOPC-21 1 4.261.4 143652.3 46.7617.3
CD-1 1 Crry-Ig 1 10.063.8 125656.0 11.261.3
Crry transgene negative 1 5.361.7 44.868.0 10.362.4
Crry transgene positive 1 3.860.8 38.867.2 13.663.6
C31/1 1 3.060.9 33.4619.1 8.562.5
C32/2 1 0.060.0 15.461.2 —a
Abbreviations are: C, clearance; Cr, creatinine; LPS, lipopolysaccharide.
a Values of CC3 5 0 were excluded from analysis
experiments between tubular staining for C3 and urinary plex. Although C3 staining was indeed absent on IF,
C3 or albumin. these mice uniformly developed renal failure.
By using these three unique experimental approaches,
we conclusively established the role of complement inDISCUSSION
LPS-induced renal injury. In this regard, it is necessary
In this study, we developed a model of sepsis-induced to emphasize that there are differences between events
acute tubular necrosis in which animals were injected occurring in complement-deficient animals and in com-
intravenously with LPS. Although LPS triggers basolat- plement-inhibited animals. The former investigates the
eral deposition of complement in the renal cortical tu- effects of complete deficiencies, while the latter deter-
bules, inhibition of this in three unique experimental mines how inhibiting complement activation will affect
methods did not prevent ARF. outcome measures. The inhibition of complement is not
The first experiment sought to inhibit the complement absolute with inhibitors, but is more relevant to clinical
cascade at the critical C3 convertase stage via injection utility, as such inhibitors are available clinically [35]. The
of the recombinant Crry-Ig concurrently with LPS. We analysis of disease models using knockouts has been
believe these studies have particular relevance given the widely used, but there are limitations for mechanistic
current availability of recombinant protein inhibitors of
analyses and assessment of therapeutic strategies. An
complement such as soluble CR1 and humanized anti-
example of this has recently been reviewed by SteinmanC5 monoclonal antibodies [9, 34, 35]. Although this
regarding the role of the cytokines tumor necrosis factor-group had a trend toward less C3 deposition by IF, it
a and lymphotoxin-a in multiple sclerosis and its mo-did not reach statistical significance. This relative lack
del, experimental autoimmune encephalomyelitis (EAE)of effect could be due to a variety of reasons. Perhaps
[36]. Specifically, although a double knockout of tumorthe synthesis of complement occurs too rapidly in com-
necrosis factor-a and lymphotoxin-a can still developparison with the diffusion of the 160 kD Crry-Ig into the
EAE with normal kinetics and manifestations, it is notrenal interstitium. Additionally, poor renal perfusion,
correct to assume that there is no role for these cytokineswhich may in fact be the primary mechanism of ARF in
in EAE and multiple sclerosis. That is because dozensthis setting, would limit delivery of Crry-Ig to the kidney.
of other mechanistic studies in animals and humans sup-Consistent with this, staining for C3 in all groups had a
port an important role for these cytokines. There aregeneral patchy quality.
several possible explanations for these findings. TheseThe transgenic mice overexpressing the murine C3
include the limitations of current knockout strategiesinhibitor Crry as a soluble protein did show notably less
because they eliminate expression of the particular genetubular C3 staining than controls. This shows that the
product throughout the body beginning with conception,increased C3 deposition seen after LPS injection requires
with likely untoward and unknown effects, and the possi-the action of the C3 convertase. The inhibition of com-
bility of disease-inducing parallel pathways that can by-plement deposition in the kidney in the Crry-transgene
pass one defect [36]. Whatever the explanation, however,group was more effective than in the Crry-Ig group,
one cannot eliminate a role for a particular proinflam-perhaps because the smaller size of the 45 kD Crry allows
matory pathway in disease using knockout strategiesit to diffuse better into the interstitial compartment. De-
alone. For this reason, we used two other strategies inspite the decrease in tubular deposition, the transgenic
addition to C32/2 mice.animals still developed ARF.
Normal mice not exposed to LPS do have interstitialFinally, because C3 occupies a pivotal role early in
staining for C3 at the basolateral aspects of cortical tu-both the classic and alternative pathways, the C32/2
bules. It seems likely this can be attributed to C3 activa-mice have no complement cascade and therefore cannot
produce C3a, C5a, or the C5b-9 membrane attack com- tion as postulated by Nath, Hostetter, and Hostetter [17],
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as it is absent in C32/2 mice [31] and factor B and interspecies differences exist in rodents’ susceptibility to
endotoxin, implying that interaction of endotoxin with aC2-deficient mice [37]. However, this degree of staining
increases significantly after LPS injection, consistent with variety of host factors is important. Thus, generalization
of these findings to humans should be made with caution.the hypothesis that increased transcription of C3 in the
renal cortex leads to increased local production and de- The phenomenon of ARF and the role of endotoxin
in causing it remain poorly understood. It may be thatposition of C3. The cortical and tubular distribution of
IF staining for C3 protein matched that seen by in situ hemodynamic factors play a more prominent role than
direct tubular injury. Furthermore, tubular cell apoptosishybridization for C3 mRNA described in previous stud-
ies [12]. In addition, there was a trend toward increased also occurs in endotoxemia [42], which is consistent with
the modest degree of tubular necrosis that we have seencirculating C3 levels following LPS administration in all
animals as a group, as has previously been described in these studies [43]. Although LPS triggers local cortical
synthesis and deposition of complement, here we have[38]. Increased synthesis of C3 following LPS administra-
tion is not restricted to proximal tubular cells, but is shown conclusively that complement activation does not
lead to the resultant ARF.instead a more general phenomenon, as shown by in-
creased C3 mRNA and protein levels in jejunal mucosa
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